Third Harmonic Bio, Inc. (THRD)
NASDAQ: THRD · Real-Time Price · USD
5.13
-0.01 (-0.19%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.

The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions.

It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.

Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Third Harmonic Bio, Inc.
Third Harmonic Bio logo
Country United States
Founded 2019
IPO Date Sep 15, 2022
Industry Biotechnology
Sector Healthcare
Employees 53
CEO Natalie Holles

Contact Details

Address:
1700 Montgomery Street, Suite 210
San Francisco, California 94111
United States
Phone 209 727 2457
Website thirdharmonicbio.com

Stock Details

Ticker Symbol THRD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001923840
CUSIP Number 88427A107
ISIN Number US88427A1079
Employer ID 83-4553503
SIC Code 2834

Key Executives

Name Position
Natalie C. Holles Chief Executive Officer and Director
Julie Person Chief Administrative Officer
Dr. Edward R. Conner M.D. Chief Medical Officer
Christopher Murphy Chief Financial and Business Officer
Jennifer Dittman Chief Operating Officer
Dr. Christopher J. Dinsmore Ph.D. Chief Scientific Officer
Steven P. Sweeney Senior Vice President of Development Operations
Dennis Dean Ph.D. Chief Non-Clinical Development Officer
Ommer Chohan Treasurer and Secretary

Latest SEC Filings

Date Type Title
Apr 25, 2025 ARS Filing
Apr 25, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 22, 2025 8-K Current Report
Apr 16, 2025 SCHEDULE 13G/A Filing
Apr 14, 2025 8-K Current Report
Apr 14, 2025 PRE 14A Other preliminary proxy statements
Mar 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2025 8-K Current Report
Mar 27, 2025 10-K Annual Report